SMYD2 and gastric cancer: SMYD2 has been shown to act as an oncogene in many cancers, including esophageal squamous cell carcinoma (ESCC), bladder cancer, gastric cancer, triple-negative breast cancer, and hepatocellular carcinoma 16-19.